Dexmedetomidine inhibits renal ischemia/reperfusion-induced inflammatory reaction

doi:10.3969/j.issn.2095-4344.2013.53.015

Abstract

Abstract:

BACKGROUND: Previous studies addressing the prevention and treatment of ischemia/reperfusion kidney damage show that, some drugs could activate or inhibit the body to protect kidney tissue, which is of great significance in renal transplantation and graft functional recovery.
OBJECTIVE: To explore the influence of dexmedetomidine on expressions of inflammatory factors and C-X-C chemokine receptor type 4 in rat with renal ischemia/reperfusion.
METHODS: Forty rats were randomly divided into four equal groups: sham group, ischemia/reperfusion group, dexmedetomidine preconditioning group and dexmedetomidine post-treatment group. Except the sham group, the right kidney was removed and the left kidney was subject to ischemia for 45 minutes and reperfusion for 60 minutes, thus establishing renal ischemia/reperfusion models in other three groups. As for preconditioning group, the rat femoral vein was punctured and transfused with 1 μg/kg dexmedetomidine for 10 minutes, followed by infusing 0.5 μg/kg dexmedetomidine for 30 minutes until ischemia occurred. As for posttreatment group, the rats were infused with 0.5 μg/kg dexmedetomidine for 30 minutes after reperfusion.
RESULTS AND CONCLUSION: Serious kidney injury, obvious inflammation, tubular dilatation, and glomerulonephritis were found in rats with renal ischemia/reperfusion. The serum interleukin-1β and tumor necrosis factor-α levels in ischemia/reperfusion, dexmedetomidine preconditioning and dexmedetomidine post-treatment groups were increased significantly (P < 0.05). The expression of serum and renal C-X-C chemokine receptor type 4 was also increased (P < 0.05). Dexmedetomidine preconditioning or post-treatment significantly decreased serum interleukin-1β and tumor necrosis factor-α levels in rats with renal ischemia/reperfusion (P < 0.05). The same decline was observed in content of serum and renal C-X-C chemokine receptor type 4 (P < 0.05). Experimental findings indicate that renal ischemia/reperfusion can cause renal injury which is characterized by inflammatory reaction. Dexmedetomidine can reduce inflammatory reactions and attenuate C-X-C chemokine receptor type 4 expression to protect the kidney.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

全文链接：

Key words: reperfusion injury, systemic inflammatory response syndrome, α-adrenergic agonist, renal transplantation

CLC Number:

R318

Chen Ke-yan, Zhang Yi-nan, Diao Yu-gang, Zhou Jin, Zhang Tie-zheng. Dexmedetomidine inhibits renal ischemia/reperfusion-induced inflammatory reaction[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(53): 9189-9195.

Figures/Tables 3

References

[1] Yoo CS, Shin YH, Ko JS, et al. Anesthetic management including extracorporeal membrane oxygenation therapy of liver transplant recipient with life-threatening hypoxemia -a case report. Korean J Anesthesiol. 2013;65(2):151-157.

[2] Duty BD, Conlin MJ, Fuchs EF, et al. The current role of endourologic management of renal transplantation complications. Adv Urol. 2013;2013:246520.

[3] Bhattacharya P, Pandey AK, Paul S, et al. Aquaporin-4 Inhibition Mediates Piroxicam-Induced Neuroprotection against Focal Cerebral Ischemia/Reperfusion Injury in Rodents. PLoS One. 2013;8(9):e73481.

[4] Acipayam M, Huseyinova G, Sunar H, et al. Examination of Ultrastructural Mechanisms of Vitamin E Efficacy to Prevention of Ischemia-Reperfusion Injury in the Lung After Cardiopulmonary Bypass. Microsc Microanal. 2005;11(S02): 1020-1021.

[5] de Vries DK, Khairoun M, Lindeman JH, et al. Renal Ischemia-Reperfusion Induces Release of Angiopoietin-2 From Human Grafts of Living and Deceased Donors. Transplantation. 2013;96(3):282-289.

[6] Ghasemzadeh M, Kaplan ZS, Alwis I, et al. The CXCR1/2 ligand NAP-2 promotes directed intravascular leukocyte migration through platelet thrombi. Blood. 2013;121(22): 4555-4566.

[7] Chang WT, Li J, Vanden Hoek MS, et al. Baicalein preconditioning protects cardiomyocytes from ischemia-reperfusion injury via mitochondrial oxidant signaling. Am J Chin Med. 2013;41(2):315-331.

[8] Pendergrass KD, Boopathy AV, Seshadri G, et al. Acute preconditioning of cardiac progenitor cells with hydrogen peroxide enhances angiogenic pathways following ischemia-reperfusion injury. Stem Cells Dev. 2013;22(17): 2414-2424.

[9] Li P, Ogino K, Hoshikawa Y, et al. AMP deaminase 3 plays a critical role in remote reperfusion lung injury. Biochem Biophys Res Commun. 2013;434(1):131-136.

[10] Suda S, Katsura K, Kanamaru T, et al. Valproic acid attenuates ischemia-reperfusion injury in the rat brain through inhibition of oxidative stress and inflammation. Eur J Pharmacol. 2013;707(1-3):26-31.

[11] Kuo KK, Wu BN, Chiu EY, et al. NO donor KMUP-1 improves hepatic ischemia-reperfusion and hypoxic cell injury by inhibiting oxidative stress and pro-inflammatory signaling. Int J Immunopathol Pharmacol. 2013;26(1):93-106.

[12] Mutoh J, Ohsawa M, Hisa H. Effect of naloxone on ischemic acute kidney injury in the mouse. Neuropharmacology. 2013; 71:10-18.

[13] Hassoun HT, Lie ML, Grigoryev DN, et al. Kidney ischemia-reperfusion injury induces caspase-dependent pulmonary apoptosis. Am J Physiol Renal Physiol. 2009; 297(1):F125-137.

[14] Ghali A, Mahfouz AK, Ihanamäki T, et al. Dexmedetomidine versus propofol for sedation in patients undergoing vitreoretinal surgery under sub-Tenon's anesthesia. Saudi J Anaesth. 2011;5(1):36-41.

[15] Gu J, Sun P, Zhao H, et al. Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice. Crit Care. 2011;15(3):R153.

[16] Olutoye OA, Glover CD, Diefenderfer JW, et al. The effect of intraoperative dexmedetomidine on postoperative analgesia and sedation in pediatric patients undergoing tonsillectomy and adenoidectomy. Anesth Analg. 2010;111(2):490-495.

[17] Afonso J, Reis F. Dexmedetomidine: current role in anesthesia and intensive care. Rev Bras Anestesiol. 2012; 62(1):118-133.

[18] Shukry M, Miller JA. Update on dexmedetomidine: use in nonintubated patients requiring sedation for surgical procedures. Ther Clin Risk Manag. 2010;6:111-121.

[19] Bollucuoglu K, Hanci V, Yurtlu S, et al. Comparison of propofol-dexmedetomidine, tiopental-dexmedeto- midine and etomidate-dexmedetomidine combinations' effects on the tracheal intubation conditions without using muscle relaxants. Bratisl Lek Listy. 2013;114(9):514-518.

[20] Shin HW, Yoo HN, Kim DH, et al. Preanesthetic dexmedetomidine 1 µg/kg single infusion is a simple, easy, and economic adjuvant for general anesthesia. Korean J Anesthesiol. 2013;65(2):114-120.

[21] Dong X, Xing Q, Li Y, et al. Dexmedetomidine protects against ischemia-reperfusion injury in rat skeletal muscle. J Surg Res. 2013. in press.

[22] Paul S, Bhattacharjee DP, Ghosh S, et al. Efficacy of intra-articular dexmedetomidine for postoperative analgesia in arthroscopic knee surgery. Ceylon Med J. 2010;55(4):111-115.

[23] Short J. Use of dexmedetomidine for primary sedation in a general intensive care unit. Crit Care Nurse. 2010;30(1):29-39.

[24] Tan JA, Ho KM. Use of dexmedetomidine as a sedative and analgesic agent in critically ill adult patients: a meta-analysis. Intensive Care Med. 2010;36(6):926-939.

[25] Awissi DK, Lebrun G, Fagnan M, et al. Alcohol, nicotine, and iatrogenic withdrawals in the ICU. Crit Care Med. 2013;41 (9 Suppl 1):S57-68.

[26] Shen M, Wu RX, Zhao L, et al. Resveratrol attenuates ischemia/reperfusion injury in neonatal cardiomyocytes and its underlying mechanism. PLoS One. 2012;7(12):e51223.

[27] Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013; 123(1):92-100.

[28] Fouad AA, Al-Mulhim AS, Jresat I, et al. Protective effects of captopril in diabetic rats exposed to ischemia/reperfusion renal injury. J Pharm Pharmacol. 2013;65(2):243-252.

[29] Cong G, Cui L, Zang M, et al. Attenuation of renal ischemia/ reperfusion injury by a polysaccharide from the roots of Dipsacus asperoides. Int J Biol Macromol. 2013;56:14-19.

[30] Zhang Y, Stevenson GD, Barber C, et al. Imaging of rat cerebral ischemia-reperfusion injury using(99m)Tc-labeled duramycin. Nucl Med Biol. 2013;40(1):80-88.

[31] Li Y, Zhu W, Tao J, et al. Fasudil protects the heart against ischemia-reperfusion injury by attenuating endoplasmic reticulum stress and modulating SERCA activity: the differential role for PI3K/Akt and JAK2/STAT3 signaling pathways. PLoS One. 2012;7(10):e48115.

[32] Takada M, Inoue KI, Koketsu D, et al. Elucidating information processing in primate basal ganglia circuitry: a novel technique for pathway-selective ablation mediated by immunotoxin. Front Neural Circuits. 2013;7:140.

[33] Mills NT, Scott JG, Wray NR, et al. Research review: The role of cytokines in depression in adolescents: a systematic review. J Child Psychol Psychiatry. 2013;54(8):816-835.

[34] Song GG, Choi SJ, Ji JD, et al. Association between interleukin-18 polymorphisms and systemic lupus erythematosus: a meta-analysis. Mol Biol Rep. 2013;40(3): 2581-2587.

[35] Maslanik T, Tannura K, Mahaffey L, et al. Commensal bacteria and MAMPs are necessary for stress-induced increases in IL-1β and IL-18 but not IL-6, IL-10 or MCP-1. PLoS One. 2012;7(12):e50636.

[36] Yokota S, Tanaka T, Kishimoto T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskelet Dis. 2012;4(6):387-397.

[37] Ogura M, Takeuchi H, Kawakubo H, et al. Clinical significance of CXCL-8/CXCR-2 network in esophageal squamous cell carcinoma. Surgery. 2013;154(3):512-520.

[38] Wang Z, Ma Q, Li P, et al. Aberrant Expression of CXCR4 and β-Catenin in Pancreatic Cancer. Anticancer Res. 2013;33(9): 4103-4110.

[39] Qiu X, Guo S, Wu H, et al. Identification of Wnt pathway, uPA, PAI-1, MT1-MMP, S100A4 and CXCR4 associated with enhanced metastasis of human large cell lung cancer by DNA microarray. Minerva Med. 2012;103(3):151-164.

[40] Pitchford SC, Lodie T, Rankin SM. VEGFR1 stimulates a CXCR4-dependent translocation of megakaryocytes to the vascular niche, enhancing platelet production in mice. Blood. 2012;120(14):2787-2795.

[41] Yu Y, Wang Y, Zhou LN, et al. ARB treatment prevents the decrease in endothelial progenitor cells and the loss of renal microvasculature in remnant kidney. Am J Nephrol. 2011; 33(6): 550-557.

[42] Bruno S, Grange C, Collino F, et al. Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. PLoS One. 2012;7(3):e33115.

[43] Dederer H, Berger M, Meyer T, et al. Structure-activity relationships of acetylcholine derivatives with Lucilia cuprina nicotinic acetylcholine receptor α1 and α2 subunits in chicken β2 subunit hybrid receptors in comparison with chicken nicotinic acetylcholine receptor α4/β2. Insect Mol Biol. 2013; 22(2):183-198.

[44] Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA. 2012;307(11):1151-1160.

[45] Zhang XY, Liu ZM, Wen SH, et al. Dexmedetomidine administration before, but not after, ischemia attenuates intestinal injury induced by intestinal ischemia-reperfusion in rats. Anesthesiology. 2012;116(5):1035-1046.

[46] Lili X, Jianjun S, Haiyan Z. The application of dexmedetomidine in children undergoing vitreoretinal surgery. J Anesth. 2012;26(4):556-561.

[47] Yang X, Zhao W, Hua C, et al. Chemotaxis and oospore formation in Phytophthora sojae are controlled by G-protein-coupled receptors with a phosphatidylinositol phosphate kinase domain. Mol Microbiol. 2013;88(2):382-394.

[48] Silva-Filho JL, Souza MC, Ferreira-Dasilva CT, et al. Angiotensin II is a new component involved in splenic T lymphocyte responses during Plasmodium berghei ANKA infection. PLoS One. 2013;8(4):e62999.